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doi:10.1Objectives: The risk of renal failure after thoracic endovascular aortic repair is not widely established. The aim
of this study was to assess the incidence and risk factors of renal failure.
Methods: Between 1998 and 2008, 175 consecutive patients underwent 210 procedures at 2 tertiary academic
institutions. Similar nephroprotective protocols and intravascular ultrasound were used. Retrospective analysis
was performed. Generalized linear model was used to identify factors associated with change in postoperative
estimated glomerular filtration rate.
Results:Underlying aortic diseases included 103 aneurysms, 72 dissections, 21 transections, and 14 penetrating
ulcers. Median preoperative estimated glomerular filtration rate was 65 mL $ min1 $ 1.73 m2. Contrast media
averaged 108.7  69.8 mL. Median estimated glomerular filtration rates within 48 hours and 30 days were 69
and 67 mL $ min1 $ 1.73 m2, respectively. Rates of acute renal dysfunction risk (>25% estimated glomerular
filtration rate decrease), acute kidney injury (>50% estimated glomerular filtration rate decrease), acute kidney
function failure (>75% estimated glomerular filtration rate decrease), and hemodialysis were 9.8% (19/193),
1.6% (3/193), 0% (0/193), and 0.5% (1/193), respectively. Rates of renal dysfunction at 1 month and 6 months
were 13.3% (10/75) and 17.7% (6/34), respectively. Risk factors for acute renal dysfunction were intraoperative
hypotension, stroke, sepsis, lengthy procedures, and number of stents; at 1 and 6 months they were increased
age, male gender, African American race, diabetes mellitus, chronic pulmonary disease, smoking, and zone
0 to 1 graft deployment. Obesity was nephroprotective.
Conclusions: Thoracic aortic endograft has a significant rate of renal dysfunction; however, it is lower in this
cohort than in previous smaller series. Routine use of intravascular ultrasound and reduced contrast may have
contributed to lower rates of renal insufficiency. (J Thorac Cardiovasc Surg 2010;140:S161-7)Thoracic endovascular aortic repair (TEVAR) has been in-
creasingly applied for various aortic diseases as a promising
alternative to the open surgical approach. Proposed advan-
tages of TEVAR include shorter operative time, less
blood loss, decreased need for general anesthesia, and shorter
hospital stays.1,2 TEVAR avoids morbid thoracotomy and
thoracoabdominal incisions, cardiopulmonary bypass, aortic
crossclamping, and in some cases hypothermic circulatory
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The Journal of Thoracic and Cardare unique to the endovascular procedures, there are
morbidities such as renal dysfunction that are subject to
both open and endovascular interventions. The risk of renal
dysfunction after TEVAR has not been well studied. There
is controversy in literature regarding the incidence of renal
dysfunction after TEVAR of thoracic aortic diseases
ranging from 1.5% to 34%.3,4 The goal of this study is to
determine the incidence of acute and chronic renal failure
after TEVAR and to identify associated risk factors.METHODS
Patient Population
From October 1998 to May 2008, 175 consecutive patients underwent
210 TEVAR procedures for descending thoracic aortic aneurysms, de-
scending thoracic aortic dissections (Stanford type B), penetrating thoracic
ulcers, and traumatic aortic transection at 2 tertiary academic institutions
(Harbor–UCLA Medical Center and University of Nebraska Medical
Center). Fifty-seven of the 210 procedures involved patients who had
previously undergone TEVAR and were analyzed further as a subgroup.
All patients signed consent forms for the use of these investigational
devices and agreed to participate in the surveillance protocols after deploy-
ment of the devices.
Inclusion and Exclusion Criteria
The study included patients with symptomatic aneurysms of the de-
scending thoracic aorta, asymptomatic aneurysms of the descending tho-
racic aorta with at least twice the size of the proximal normal aorta,iovascular Surgery c Volume 140, Number 6S S161
Aortic Symposium 2010 Pisimisis et alTABLE 2. RIFLE criteria for the classification of acute kidney injuryAbbreviations and Acronyms
ARF ¼ acute renal failure
CKD ¼ chronic kidney disease
CT ¼ computed tomography
eGFR ¼ estimated glomerular filtration rate
IQR ¼ interquartile range
IVUS ¼ intravascular ultrasound
RIFLE ¼ Risk of acute renal dysfunction, Injury
to the kidney, Failure of kidney
function, Loss of kidney function,
End-stage kidney disease
TEVAR ¼ thoracic endovascular aortic repair
complicated acute Stanford type B aortic dissections, aneurysmal degener-
ation of chronic Stanford type B aortic dissections, symptomatic penetrat-
ing aortic ulcers, and traumatic aortic transections. Other inclusion criteria
were signing the informed consent and agreeing to be followed up in the
institutional surveillance program. Furthermore, the patient’s arterial anat-
omy must have met device-specific requirements to be a candidate for TE-
VAR. Adequate proximal and distal landing zone and adequate-sized
access vessels were evaluated before TEVAR was offered to the patients.
Exclusion criteria were applied to patients with diseases of the ascend-
ing aorta, connective tissue disorders, pregnancy, age below 18 years, sys-
temic infection, and hypercoagulable state. Patients were also excluded if
stent-graft placement was technically unsuccessful (n ¼ 3), if they died in
the operating room but before procedure initiation (n ¼ 2), or if they were
already undergoing dialysis before the procedure (n ¼ 6).
Definitions
Aortic ulceration is defined an ulcer penetrating the elastic lamina into
the tunica media associated with hematoma within the aortic wall. Acute
aortic dissection is considered an acute event if it occurred within the first
14 days from onset of symptoms and as chronic if it occurred after 14 days
Aortic transection typically involves the intima and media, is nearly always
transverse to the axis of the vessel, andmay be complete or incomplete. The
term ‘‘complicated dissection’’ was defined as persistent/unrelenting back
pain despite maximal medical therapy, uncontrollable hypertension, aortic
enlargement more than 5 mm per year, malperfusion syndromes, or (immi-
nent) rupture.5 The patient’s clinical health status was evaluated according
to the classification of the American Society of Anesthesiologists.6 Base-
line glomerular filtration rate was calculated with the abbreviated Modifi-
cation of Diet in Renal Disease formula7 (estimated glomerular filtration
rate [eGFR] [mL $ min1 $ 1.73 m2] ¼ 186 3 [serum creatinine]1.154 3
[age]0.203 3 [0.742 if female] 3 [1.210 if African American]). Chronic
kidney disease (CKD) was defined as a baseline eGFR of 60 mL $ min1
$ 1.73 m2 or less, and chronic renal failure was defined as eGFR of 30TABLE 1. National Kidney Foundation classification of stages for
CKD
Stage Description GFR
1 Kidney damage with
normal or [ GFR
>90 (with CKD
risk factors)
2 Kidney damage with
mild or Y GFR
60–89
3 Moderate Y GFR 30–59
4 Severe Y GFR 15–29
5 Kidney failure <15 (or dialysis)
CKD, Chronic kidney disease; GFR, glomerular filtration rate.
S162 The Journal of Thoracic and Cardiovascular SurmL $min1 $ 1.73 m2 or less (stage III vs IVand Vaccording to the Kidney
Disease Outcome Quality Initiative)8 (Table 1). The most recent proposal
for a consensus definition for acute renal failure (ARF) stems from the
Acute Dialysis Quality Initiative group,9 which suggested criteria for 3
grades of increasing severity—risk of acute renal dysfunction (R), injury
to the kidney (I), failure of kidney function (F)—and 2 outcome classes—
loss of kidney function (L) and end-stage kidney disease (E) (Table 2). The
RIFLE classification, based on eGFR and serum creatinine, was applied to
postoperative diagnosis of acute renal dysfunction. Postprocedure RIFLE
class R was defined accordingly as eGFR decline of more than 25% or se-
rum creatinine increase 31.5 compared with baseline, RIFLE class I as
eGFR decline of more than 50% or serum creatinine increase 32 com-
pared with baseline, and RIFLE class F as eGFR decline of more than
75% or serum creatinine increase33 compared with baseline or acute se-
rum creatinine greater than 4 mg/dL, all based on nadir eGFR/peak creat-
inine values within 48 hours after the procedure. The patients’ renal
function was monitored postoperatively as an outpatient at 1 month and
6 months.
Imaging Protocol
Thepatientsunderwent computed tomographic (CT) scansusinga64-slice
scannerwith 3-mmcollimation and 3:5 pitch. All patients except 6 underwent
CT scans with electrocardiographic gating. Images were reconstructed us-
ing 50% overlap. All patients received Omnipaque (General Electric, Fair-
field, Conn); 150 mL was injected at a rate of 3 mL/s using a power
injector, and the scan was initiated 30 seconds after the start of the contrast
injection. No trailing saline bolus was used. Approximately 20% of patients
had CT scans performed at outside institutions, using similar protocols.
The intraoperative imaging included pulsed and regular fluoroscopy, as
well as intravascular ultrasound (IVUS) (Volcano Therapeutics, Inc, La-
guna Hills, Calif). The procedure was started with open exposure of pre-
screened femoral artery, placement of a 9F sheath, and IVUS
interrogation: the IVUS measures diameter of the ipsilateral (and if neces-
sary contralateral) external and common femoral arteries. This is important
to assure that the access vessel will accommodate the selected stent graft.
Amount of calcification, intramural abnormalities, and tortuosity is also ac-
curately assessed by IVUS. Next, the IVUS is advanced to the area of in-
terest, where proximal and distal landing zones are evaluated for any
thrombus or calcium. Next, by use of the IVUS, the diameters of the prox-
imal and distal landing zones are measured, and the aortic branch vessels
are marked on the fluoroscopic screen. Furthermore, the treatment length
(distance between proximal and distal landing zones as well as any stent-
graft overlap) is measured with IVUS by the pull-back method. With the
information above, the appropriate stent grafts are chosen and introduced
to the area of interest. A pre-deployment angiogram may be performed
to reconfirm the location of the branch vessels (but this is not necessary).
Subsequent to stent-graft deployment, the apposition of the graft and poten-
tial endoleaks are assessed by IVUS and treated with ballooning orClass GFR criteria
Risk Plasma creatinine increase 1.5 3 baseline
or GFR decline>25%
Injury Plasma creatinine increase 2 3 baseline
or GFR decline>50%
Failure Plasma creatinine increase 3 3 baseline or GFR
decline>75% or acute plasma creatinine>4 mg/dL
Loss Persistent ARF ¼ complete loss of kidney function
requiring dialysis for>4 weeks but<3 months
End stage End-stage kidney disease requiring dialysis for>3 months
RIFLE, Risk, Injury, Failure, Loss, End-stage kidney disease; GFR, glomerular filtra-
tion rate; ARF, acute renal failure.
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TABLE 3. Demographics and comorbidities of patients treated by
TEVAR
Characteristics All patients (n ¼ 210)
Age IQR (58–78 y) 70
Gender (male) 132 (62.9%)
Gender (female) 78 (37.1%)
Race (African American) 9 (4.2%)
Coronary artery disease 61 (29.1%)
Hypertension 128 (60.9%)
Acute myocardial infarction (<14 d) 7 (3.3%)
Congestive heart failure 17 (8.1%)
Diabetes mellitus 20 (9.5%)
Peripheral arterial disease 29 (13.8%)
Other vascular disease (vasculitis, Marfan) 5 (2.3%)
Preoperative stroke 21 (10%)
Chronic obstructive pulmonary disease 39 (18.5%)
Obesity (body mass index  30 kg/m2) 11 (5.2%)
Hyperlipidemia 18 (8.5%)
History of smoking 96 (45.7%)
History of malignancy 10 (4.7%)




Previous aortic surgery 80 (38.1%)
Previous cardiac surgery 22 (10.5%)
Previous trauma 11 (5.2%)
TEVAR, Thoracic endovascular aortic repair; IQR, interquartile range.
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firmation.
The protocol for postoperative imaging includes a 3-phasemultidetector
CT angiogram. A noncontrast scan (baseline) through the chest and abdo-
men is followed by contrast CTangiography using 100mL of nonionic con-
trast (arterial phase). A 2-minute delayed CT scan is performed (venous
phase) to enhance detection rate for endoleaks. All elective patients under-
went a 3-dimensional centerline-of-flow reconstruction to evaluate for ac-
cess vessels and choose the appropriate stent graft based on proximal and
distal landing zone and treatment length.
Periprocedural Management of Patients
All patients with baseline CKD stage II (eGFR<90 mL $ min1 $ 1.73
m2) who underwent elective TEVAR received peri-interventional intrave-
nous hydration with 0.9% saline solution, and all potentially nephrotoxic
drugs were discontinued before the procedure. General anesthesia was
used in 37% (n ¼ 77) of the procedures and local/regional in 63% (n ¼
133). In brief, TEVAR was performed in an operating room equipped
with a portable fluoroscopy or endovascular suite with a fixed imaging
unit. Percutaneous femoral, radial, or brachial access was used to introduce
an angiographic catheter proximal to the area of interest. Then, 40 mL of
nonionic, hypoosmolar contrast medium (iohexol, Omnipaque) injected
at flow rates of 20 mL/s using an automated power injector. In 43 (20%)
patients an iliac conduit was necessary owing to small common femoral ar-
teries. IVUS was used to interrogate the access vessel, the visceral and tho-
racic aorta, and its branches. The stent grafts were chosen on the basis of
preoperative CT scan, intraoperative angiogram, and the IVUS measure-
ments. Additional angiograms and IVUS interrogations were performed
before and after deployment of the stent graft. Adenosine injections (36
mg followed by 18 mg for each subsequent dose) and right ventricular pac-
ing were used for anti-impulsive therapy during deployment and balloon
dilatation of the stent grafts in landing zone 2 and lower.
Statistical Analysis
Perioperative data including demographics, cardiovascular risk factors,
preoperative renal function, operative technical details, intraoperative he-
modynamic parameters and fluid balance details, and postoperative com-
plications specifically for renal function as well as overall morbidity
were summarized using descriptive statistics. Generalized linear model
was used to evaluate these factors for an association with change in
eGFR at various time points within follow-up. In the framework of gener-
alized linear model, stepwise model selection procedure based on multiple
criteria including Akaike information criterion, corrected Akaike informa-
tion criterion, and Bayesian information criterion was applied to select the
subset of factors, which has a statistically significant effect on the change of
eGFR at different time points. A significance level of 5% was used for all
analyses. The analyses were carried out using SAS version 9.2 (SAS Insti-
tute, Inc, Cary, NC).RESULTS
A total of 175 consecutive patients underwent 210 endo-
vascular procedures. Single repair was performed in 152 pa-
tients, whereas 23 had subsequent repairs. Of the 210
procedures, 132 (63%) were performed on male patients
and 78 (37%) on female patients. Median age for the whole
group was 70 years (interquartile range [IQR] 58–78 years).
The majority of patients were evaluated as high-risk candi-
dates for an open repair. The most commonly encountered
comorbidities were hypertension (61%), smoking history
(46%), coronary artery disease (29%), and previous aortic
surgery (38%), as summarized in Table 3. Emergency TE-The Journal of Thoracic and CardVARwas performed in 42 (20%) patients for contained aor-
tic rupture and 29 (14%) patients were in meta-stable
condition on arrival in the operating room. Proximal land-
ing zone distribution was 2 and lower for 25% (52/210)
of patients (Figure 1). The underlying disease of patients
undergoing TEVAR is summarized in Table 4.Renal Function
The stratification of preoperative renal function in
the studied patient cohort, based on eGFR, is shown in
Table 5. Only 24% (50/210) had normal preoperative renal
function (eGFR>90 mL $min1 $ 1.73 m2), whereas 39%
(81/210) had an eGFR less than 60 mL $ min1 $ 1.73 m2
and 3% (6/210) were undergoing hemodialysis at the
time of presentation. The average volume of procedural
contrast used was 108.7  69.8 mL (IQR: 60–150 mL).
The median baseline eGFR was 65 mL $ min1 $ 1.73 m2
(IQR 47–86 mL $min1 $ 1.73 m2). In the immediate post-
operative period, the median eGFR was 69 mL $ min1 $
1.73 m2 (IQR: 46–95 mL $ min1 $ 1.73 m2). At 30 days
after the procedure, the median eGFR was 67 mL $ min1
$ 1.73 m2 (IQR: 48–88 mL $ min1 $ 1.73 m2) as shown
in Table 5. After the renal function at 6 months there was
a decrease in median eGFR to 59 mL $ min1 $ 1.73 m2
(IQR: 41–95 mL $ min1 $ 1.73 m2).
The rate of acute worsening in renal function from base-
line was evaluated with the RIFLE criteria (Figure 2). Weiovascular Surgery c Volume 140, Number 6S S163
FIGURE 1. Proximal landing zones for all patients undergoing thoracic
endovascular repair. Zone 0, Covering the innominate artery; zone I, cover-
ing the left carotid artery; zone II, covering the left subclavian artery; zone
III, involving the proximal one third of the descending thoracic aorta; zone
IV, involving the distal two thirds of the descending thoracic aorta.
TABLE 5. Preoperative and postoperative renal function
characteristics of patients undergoing TEVAR
Parameter Median IQR n
Preop eGFR 65 47-86 204
Postop eGFR (24 h) 69 46-95 197
Postop eGFR (30 d) 67 48-88 75
Postop eGFR (6 mo) 59 41-95 34
Preoperative hemodialysis (chronic) — — 6
Total — — 210
TEVAR, Thoracic endovascular aortic repair; IQR, interquartile range; eGFR, esti-
mated glomerular filtration rate (mL $ min1 $ 1.73 m2).
Aortic Symposium 2010 Pisimisis et alobserved more than 25% acute decrease in eGFR in 19
(9.8%) of 193 patients, more than 50% decrease of eGFR
in an additional 3 (1.6%), and there were no patients with
greater than 75% decline in eGFR. However, a 65-year-
old male patient with descending thoracic aortic aneurysm
required postoperative hemodialysis (0.5%). He had base-
line CKD stage 4, grade 4 aortic calcifications, and had an
embolic frontal stroke and renal failure. He died on the sev-
enth postoperative day.
At 1 month’s follow-up, 10 (13.3%) of 75 patients had
significantly worsening renal function; the observed rate
at 6 months (Figure 3) was 17.7% (6/34), enough to be cat-TABLE 4. Underlying pathology of patients undergoing TEVAR
Aortic pathology n
Aneurysm 103 (49%)
Acute aortic dissection (14 d) 43 (20.5%)
Chronic aortic dissection (14 d) 29 (13.8%)
Aortic transection 21 (10%)
Penetrating ulcer 14 (6.7%)
Total 210
TEVAR, Thoracic endovascular aortic repair.
S164 The Journal of Thoracic and Cardiovascular Suregorized at a higher CKD stage on the basis of the National
Kidney Foundation staging system. No additional patients
began requiring hemodialysis in the follow-up period.
Statistical model selection procedure (multivariate anal-
ysis) was performed to identify factors associated with de-
creased eGFR (P<.05). Risk factors associated with acute
decrease in eGFR were intraoperative hypotension, perio-
perative stroke, postoperative sepsis, and lengthy proce-
dures. Increasing numbers of deployed stent grafts were
also associated with decreased eGFR in correlation analy-
sis. At 1 and 6 months, prognostic factors for worsening re-
nal function included increased age, male gender, African
American race, diabetes mellitus, hypertension, chronic ob-
structive pulmonary disease, smoking history, prior stroke
or paraplegia, and arch zone 0 to 1 graft deployment. The
analysis model identified obesity (body mass index> 35
kg/m2) as a nephroprotective factor (P < .05) for bothFIGURE 2. Rates of acute decline in renal function from baseline after
TEVAR. RIFLE classification: class R, risk of acute renal dysfunction
(eGFR decline> 25%); class I, injury to the kidney (eGFR decline>
50%); class F, failure of kidney function (eGFR decline> 75%). AKI,
Acute kidney injury; ARF, acute renal failure; HD, hemodialysis; TEVAR,
thoracic endovascular aortic repair; eGFR, estimated glomerular filtration
rate.
gery c December 2010
FIGURE 3. Rate of worsening renal function from baseline, at one and six
months after TEVAR. HD, Hemodialysis; eGFR, estimated glomerular fil-
tration rate; TEVAR, thoracic endovascular aortic repair.
TABLE 6. Risk factors associated with decrease of eGFR acutely
(24 hours) and at 1 month and 6 months
Prognostic factor F value P value
Twenty-four hours (n ¼ 193)
Gender (male) 5.25 .02331
Congestive heart failure 9.76 .00214
Smoking 4.56 .03432
Intraoperative hypotension 3.14 .07822
Adenosine 6.73 .01044
Postop bleed 0.00001 .99715
Hemodialysis 2.25 .13572
Coronary artery disease 8.62 .00385
Hypertension 3.28 .07209
Age 20.08 .00001
Blood urea nitrogen 35.78 .00000
Creatinine 11.06 .00111
PRBC (units of blood) 3.13 .07862
One month (n ¼ 79)
Gender (male) 7.90 .00645
Diabetes mellitus 6.81 .01108
Smoking 5.77 .01901
Race (African American) 5.05 .02784
Aortic arch zone 3.15 .03029
Age 20.00 .00003
Blood urea nitrogen 13.82 .00041
Six months (n ¼ 37)
Preoperative stroke 10.83 .00249
COPD 5.43 .02647
Stroke (intraop and postop) 20.36 .00009
Paraplegia 8.80 .00575
Arterial dissection/injury 7.65 .00944
eGFR, Estimated glomerular filtration rate; PRBC, packed red blood cells; COPD,
chronic obstructive pulmonary disease.
Pisimisis et al Aortic Symposium 2010short-term and long-term renal function after TEVAR
(Table 6).
DISCUSSION
The emergence of TEVARhas been associated with lower
rates of in-hospital morbidity and early mortality than those
of open surgery in selected patient cohorts.3,10,11 However,
the incidence of acute and chronic renal dysfunction in
patients undergoing TEVAR has not been well defined.
This is partially because there is no consistent definition
for ARF used by various authors12 and there is more than
1 parameter related to renal function monitoring. The ab-
sence of studies specifically designed to look into various
parameters of renal function after TEVAR makes it difficult
to compare rates of ARF reported by authors in various tri-
als.3,11,13-17 These studies would use arbitrarily cutoff points
for absolute or relative creatinine increase. To our
knowledge, this is the only study using eGFR for follow-
up after TEVAR. eGFR is a more sensitive indicator of renal
function than creatinine and is recommended by Acute Di-
alysis Quality Initiative Group9 as well as Jin and coau-
thors.7 Furthermore, eGFR accounts for the variability of
creatinine resulting from age, race, and gender and can be
used as a risk factor to predict long-term survival.18
In regard to the immediate postoperative period, renal
dysfunction was classified after the RIFLE criteria as sug-
gested by the Acute Dialysis Quality Initiative Group.9
This grading system is sensitive to early changes in kidney
function and is an independent predictor of hospital mortal-
ity in a large heterogeneous population of critically ill pa-
tients.19 Furthermore, in patients undergoing aortic arch
replacement with hypothermic circulatory arrest, the RI-
FLE classification was able to readily identify acute kidney
injury as risk factor for mortality.20 The authors plead for
widespread use of internationally accepted classificationsThe Journal of Thoracic and Cardfor acute and chronic renal dysfunction in future studies.
This allows for true ‘‘apple to apple’’ comparison of various
studies on renal dysfunction.
The rate of acute worsening renal function remains high
in survivors after TEVAR (11.9%). This includes a patient
(0.5%) in the cohort who required postoperative hemodial-
ysis. Preoperative poor renal dysfunction, intraoperative use
of contrast material, perioperative hypotension, and aortic
plaque embolization are some of the major reasons for
this significant rate of worsening renal function. However,
the overall rate of acute renal dysfunction after TEVAR in
this study compares favorably with the results from other
centers that used similar criteria for acute renal insuffi-
ciency. In a cohort of 97 patients, Eggebrecht and coau-
thors4 report ARF in 34% of patients after TEVAR
(increase>25% and/or>0.5 mg/dL in pre-procedural se-
rum creatinine at 48 hours), including 3% of patients in
need of hemodialysis. The average use of 307  188 mL
of nonionic contrast medium is more than twice that in cur-
rent study. In a series of 38 patients undergoing complex en-
dovascular thoracoabdominal aneurysm repair, Chang and
coworkers21 report 32% of patients with postoperativeiovascular Surgery c Volume 140, Number 6S S165
Aortic Symposium 2010 Pisimisis et alacute renal insufficiency (increase 50% in pre-procedural
serum creatinine) and use of 170  85 mL contrast.
Probable explanation for the lower renal dysfunction rate
in the current study is the IVUS-guided TEVAR and reduced
use of contrast material. Although the amount of contrast
failed to reach statistical significance in the statistical analy-
sis, the authors suspect that this study was underpowered to
find the correlation. Inasmuch as the current study reports
one of the lowest average amounts of contrast material used
in any large-scale TEVAR study, the number of procedures
needed to reach statistical significance is much higher than
in most other published series. Contrast nephropathy is
a widely recognized culprit for renal dysfunction, especially
in patients with pre-existing renal insufficiency.22 IVUS-
assisted TEVAR reduces the use of contrast material: IVUS
assists with measurements of proximal and distal landing
zones, gauging the access vessels and checking stent-graft
apposition and any evidence of endoleaks. All these maneu-
vers reduce the intraoperative use of contrast. As described in
the section on imaging protocol, IVUS may effectively re-
duce the contrast material to the amount needed for comple-
tion angiogram and management of any endoleaks. IVUS,
along with fluoroscopy, provides almost all information
given by angiogram. The study provides the lowest amount
of contrast use in any large-scale TEVAR study, and the au-
thors attribute this to systematic use of IVUS. Furthermore,
IVUS allows for fewer wire manipulations and less risk of
distal atheromatous microembolization. Thoracic and ab-
dominal aortic stent grafting with fluoroscopy and IVUS is
feasible in patients with advanced renal disease.23,24
At 1 and 6 months, 13.3% and 17.7% of the patients pro-
gressed to a higher stage of chronic kidney injury, respec-
tively. Other longitudinal follow-up for TEVAR using
eGFR and standard kidney failure classification does not ex-
ist in the literature to allow for comparison. However there
seems to be a persistent risk for renal insufficiency for sev-
eral months after TEVAR. Possible causes for that include
need for repeat contrast imaging to assess and follow up TE-
VAR for endoleak, along with progression of atheroscle-
rotic disease.
The prognostic factors for worsening kidney function
computed with multivariate analysis are TEVAR-related
and patient-related. Advanced age, coronary artery disease,
smoking, hypertension, and diabetes are known risk factors
for atherosclerosis and therefore could affect renal function
indirectly via progression of atherosclerotic disease or
through increased intraoperative atheroemboli from wire
and catheter manipulation. Preoperative eGFR was also
a risk factor in our study group, as shown in previous stud-
ies.4,21 Optimization of the aforementioned comorbidities
and adequate hydration of the patients at risk before
TEVAR may decrease the risk of postoperative renal
insufficiency. In fact, this is probably the reason for
increase in median eGFR in the first 48 hours afterS166 The Journal of Thoracic and Cardiovascular SurTEVAR; most patients underwent at least 24 hours of
perioperative hydration. Intraoperative parameters, such as
lengthy procedures, multiple stents, and more proximal
deployment zones, all increased the risk of acute kidney
injury likely by reflecting the need for more contrast and
endovascular manipulations resulting in risk for contrast
nephropathy, renal microembolism, and inflammatory
response. Other prognostic factors identified, such as
periprocedural hypotension, bleeding, and sepsis, are
likely related to ischemic kidney injury and should be
treated promptly and aggressively. Therefore, optimization
of the identified risk factors should be adopted as part of
the patients’ preparation for TEVAR and perioperative
management.
Of interest, obese patients were less likely to have renal
dysfunction in short- and midterm-term follow-up, possibly
reflecting the higher blood volume of that patient group, al-
lowing for lower plasma concentration of contrast material
and better volume reserve in case of blood loss.
There are multiple limitations to this study. It represents
a retrospective analysis of prospectively collected data as
part of an investigational protocol. There is no risk-
adjusted control group. Furthermore, the follow-up on
eGFR values is incomplete. This may limit the conclusions.
One may raise the argument that the missing midterm and
long-term eGFR data may have affected the results. A larger
trial using a multicenter registry is recommended to sub-
stantiate the prognostic findings in this study.
In conclusion, worsening renal function is one of the most
common morbidities after TEVAR. It is worrisome in this
population with frequent imaging surveillance. The rate of
renal dysfunction seems to be lower than in other studies,
possibly owing to decreased use of contrast material and fre-
quent IVUS imaging. Risk factors for deteriorating renal
functionwere computed at 2 days, 1month, and 6months af-
ter TEVAR.Modification of identified perioperative risk fac-
torsmay further decrease the incidence of renal dysfunction.
We thank Dr Xiang Fang, the Director of Department of Biosta-
tistics at Creighton University, for advanced statistical computa-
tions in this study.
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